{"filing":{"accession_number":"0001395064-26-000331","cik":"0001395064","ticker":"TKPHF","company_name":"TAKEDA PHARMACEUTICAL CO LTD","form":"6-K","filing_date":"2026-08-28","report_date":"2026-08-28","primary_document":"form6k_082826.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1395064/000139506426000331/form6k_082826.htm"},"events":[{"id":30449,"run_id":27906,"accession_number":"0001395064-26-000331","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This is a press release announcing U.S. FDA approval of MIMRYLO™ (rusfertide), a first-in-class hepcidin mimetic for treating polycythemia vera. The disclosure is a material regulatory milestone and product approval event. While it is not a discrete M\u0026A transaction, earnings release, or executive change, it represents a significant operational and commercial milestone—the successful regulatory approval of a novel therapeutic product that Takeda has exclusive global development and commercialization rights for. The filing explicitly states \"This approval does not result in any changes to Takeda's consolidated financial forecast for the fiscal year ending March 31, 2027,\" confirming this is a regulatory event rather than a financial restatement or guidance change. The event is material to investors assessing Takeda's pipeline, competitive position, and future revenue potential in oncology/rare diseases.","company_name":"TAKEDA PHARMACEUTICAL CO LTD","ticker":"TKPHF","filing_date":"2026-08-28","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":33045,"accession_number":"0001395064-26-000331","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This is a press release announcing U.S. FDA approval of MIMRYLO™ (rusfertide), a first-in-class hepcidin mimetic for treating polycythemia vera. The disclosure is a material regulatory milestone and product approval event. While it is not a discrete M\u0026A transaction, earnings release, or executive change, it represents a significant operational and commercial milestone—the successful regulatory approval of a novel therapeutic product that Takeda has exclusive global development and commercialization rights for. The filing explicitly states \"This approval does not result in any changes to Takeda's consolidated financial forecast for the fiscal year ending March 31, 2027,\" confirming this is a regulatory event rather than a financial restatement or guidance change. The event is material to investors assessing Takeda's pipeline, competitive position, and future revenue potential in oncology/rare diseases.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-31T11:00:11.306141+00:00","company_name":"TAKEDA PHARMACEUTICAL CO LTD","ticker":"TKPHF","filing_date":"2026-08-28"}]}